Danaher Co. (NYSE:DHR) Shares Sold by ING Groep NV

ING Groep NV reduced its holdings in Danaher Co. (NYSE:DHR) by 39.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,964 shares of the conglomerate’s stock after selling 56,816 shares during the quarter. ING Groep NV’s holdings in Danaher were worth $23,900,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher during the 2nd quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $51,000. Financial Connections Group Inc. bought a new stake in Danaher during the 2nd quarter worth about $51,000. Finally, Western Pacific Wealth Management LP bought a new stake in Danaher during the first quarter worth about $55,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR traded down $1.90 during mid-day trading on Thursday, hitting $239.63. The stock had a trading volume of 804,589 shares, compared to its average volume of 2,737,046. The company has a 50 day moving average of $263.42 and a two-hundred day moving average of $260.64. The firm has a market cap of $173.08 billion, a PE ratio of 46.08, a PEG ratio of 4.40 and a beta of 0.85. Danaher Co. has a twelve month low of $204.15 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the company earned $2.02 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is presently 20.61%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent analyst reports. Robert W. Baird lowered their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Finally, TD Cowen upped their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.